Page 111 - Read Online

Page 8 of 8 Gómez-Mendoza et al. Metab Target Organ Damage. 2025;5:24 https://dx.doi.org/10.20517/mtod.2024.108

liver disease. World J Gastroenterol. 2017;23:8263-76. DOI PubMed PMC
21. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of
research gaps. Hepatology. 2019;70:1457-69. DOI PubMed PMC
22. Fernandes MT, Ferraro AA, de Azevedo RA, Fagundes Neto U. Metabolic differences between male and female adolescents with non-
alcoholic fatty liver disease, as detected by ultrasound. Acta Paediatr. 2010;99:1218-23. DOI PubMed
23. Hartmann P, Schnabl B. Risk factors for progression of and treatment options for NAFLD in children. Clin Liver Dis. 2018;11:11-5.
DOI PubMed PMC
24. Nobili V, Socha P. Pediatric nonalcoholic fatty liver disease: current thinking. J Pediatr Gastroenterol Nutr. 2018;66:188-92. DOI
PubMed
25. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver
Dis. 2012;32:3-13. DOI PubMed
26. Kwon Y, Jeong SJ. Relative skeletal muscle mass is an important factor in non-alcoholic fatty liver disease in non-obese children and
adolescents. J Clin Med. 2020;9:3355. DOI PubMed PMC
27. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of
nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835. DOI PubMed PMC
28. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: update and
impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver
disease. Hepatology. 2024;79:1212-9. DOI PubMed
29. Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1:
definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. DOI PubMed
30. Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement
on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6:65-72. DOI PubMed
31. Xing Y, Fan J, Wang HJ, Wang H. Comparison of MAFLD and NAFLD characteristics in children. Children. 2023;10:560. DOI
PubMed PMC
32. Sessa A, Guarino S, Umano GR, Miraglia Del Giudice E, Marzuillo P. MASLD vs. NAFLD: a better definition for children with
obesity at higher risk of kidney damage. J Hepatol. 2024;80:e87-9. DOI PubMed
33. Sanchez-Torres C, Ramirez Tovar A, Chatman K, et al. Concordance of MASLD and NAFLD nomenclature in youth participating in
the TARGET-NASH real-world cohort. Hepatol Commun. 2024;8:e0546. DOI PubMed PMC